A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.
about
ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2).Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale.p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies.The role of molecular genetic analysis within the diagnostic haemato-oncology laboratory.Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia.Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: five cases, a literature review and discussion of management.The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications.The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.Chronic lymphocytic leukemia-associated chromosomal abnormalities and miRNA deregulation.Functional assessment of p53 in chronic lymphocytic leukemia.Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities.The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13).
P2860
Q30768193-EC93B28B-8BF8-4AE7-BB77-E7D2BCD9E312Q33409459-6ABAEB92-66DF-4CC1-89F1-5993689A0C1BQ34461989-3A6B1AC5-0085-454E-8FBE-A3FB71F07648Q35597328-F39344EF-BD42-4609-9707-67FE7B257176Q36022313-F4313B83-6B0A-46A7-B545-3DB7FEE958E6Q36967158-C72F2DA0-E340-435F-9C76-D7D58A65775EQ37325003-6750EA94-F2C6-4326-9747-89EDF0F3470FQ37433613-35928EBD-A648-486C-9521-7E3C7E2F2AC2Q37874926-9877A96F-DC6A-4D28-B306-3391B200A3CDQ37924989-9CD43A2B-3ABD-4600-B39C-2770DEE2BCC9Q37978967-9A7EE3B0-9D1C-4C77-89AA-F459EA84E0F7Q37980658-E73A7CB3-213D-4A12-A07E-AB233B7EDADCQ38008448-CF911E77-9C15-491F-9C4C-C373BC1F9F17Q38101382-071AEE15-9583-42A1-ADC7-F0602EC3A86EQ38254406-1D80069E-5865-49A8-B092-BED7E3B2E668Q38286344-E0BA9B8C-A913-4800-AC04-E647BEFB2ADFQ38895643-DDA8F283-94AE-491A-A6ED-C9C6AD6DFD0DQ39339803-15E8BB37-37FC-4285-A730-0CCBD71817D5Q39431815-802E9595-FEF8-4458-81B7-85B5503B9B6FQ39670490-878711CC-D039-4871-97B9-7A6F1D67C714Q40298340-7F1EC646-DFB4-494B-BABF-0155138BB469Q43627273-B2F8B30D-43F1-47D9-B442-28F95BDEC44FQ54675272-5727B222-D328-47BD-95C8-35615437EA3E
P2860
A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
A novel functional assay using ...... ATM and TP53 mutations in CLL.
@en
A novel functional assay using ...... ATM and TP53 mutations in CLL.
@nl
type
label
A novel functional assay using ...... ATM and TP53 mutations in CLL.
@en
A novel functional assay using ...... ATM and TP53 mutations in CLL.
@nl
prefLabel
A novel functional assay using ...... ATM and TP53 mutations in CLL.
@en
A novel functional assay using ...... ATM and TP53 mutations in CLL.
@nl
P2093
P2860
P50
P356
P1433
P1476
A novel functional assay using ...... ATM and TP53 mutations in CLL
@en
P2093
A C Gardiner
A Skowronska
D G Oscier
R Ibbotson
R Walewska
P2860
P2888
P304
P356
10.1038/SJ.LEU.2405092
P577
2008-01-17T00:00:00Z